系统性红斑狼疮孕妇的药物使用趋势及与非狼疮孕妇的比较
基于瑞典医学出生登记(2006-12年)的队列研究,纳入483例SLE妊娠和5723例非SLE妊娠,分析孕前3个月至产后6个月的处方药配药情况。SLE妊娠中49.3%使用DMARDs、48.0%使用糖皮质激素、40.8%使用阿司匹林,常见药物(如达肝素、对乙酰氨基酚、左甲状腺素)使用率较非SLE妊娠高1.2至20倍。
要点
- SLE妊娠中近半数配药DMARDs和糖皮质激素,阿司匹林使用率达40.8%。
- SLE妊娠常见药物使用率显著高于非SLE妊娠,如达肝素20.9% vs 1.0%。
- 需研究SLE妊娠常用药物对妊娠、母乳及子代长期结局的获益与风险。
核心结论
- SLE妊娠中近半数使用DMARDs和糖皮质激素,常见药物使用率远高于非SLE妊娠。
研究设计与样本
- 基于瑞典医学出生登记(2006-12年)的队列研究,纳入483例SLE妊娠和5723例非SLE妊娠,分析孕前3个月至产后6个月的处方配药。
主要发现
- SLE妊娠中DMARDs配药率为49.3%,糖皮质激素为48.0%,阿司匹林为40.8%,其他NSAIDs为6.0%,且随妊娠时期变化。
- SLE妊娠常见药物配药率较非SLE妊娠高1.2至20倍,如达肝素20.9% vs 1.0%、对乙酰氨基酚18.2% vs 2.9%、左甲状腺素15.9% vs 4.9%。
关键数值与推荐
- SLE妊娠中DMARDs配药率49.3%,糖皮质激素48.0%,阿司匹林40.8%,其他NSAIDs 6.0%。
- 达肝素在SLE妊娠中配药率20.9%,非SLE妊娠1.0%。
- 对乙酰氨基酚在SLE妊娠中配药率18.2%,非SLE妊娠2.9%。
- 左甲状腺素在SLE妊娠中配药率15.9%,非SLE妊娠4.9%。
临床怎么用
- 提示SLE孕妇常用药物负担高,临床需关注DMARDs、激素及阿司匹林等药物的妊娠期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to characterize SLE medication trends before, during and after pregnancy and to compare other commonly used medications during SLE pregnancies with non-SLE pregnancies. METHODS: Women with pregnancies ending in live birth or stillbirth were identified from the Swedish Medical Birth Register (2006-12). National registers were used to identify women with prevalent SLE during pregnancy and a sample without SLE and to identify prescription medications dispensed from 3 months pre-pregnancy until 6 months postpartum. We reported the prevalence of DMARDs, systemic CSs and NSAIDs (aspirin reported separately) in SLE pregnancies. We calculated prevalence estimates of other medications that were dispensed during pregnancy to ⩾ 5% of SLE pregnancies and for the same medications among non-SLE pregnancies. RESULTS: There were 483 pregnancies among women with SLE and 5723 pregnancies among women without SLE. In SLE pregnancies, 49.3% had one or more dispensing for DMARDs during pregnancy; the prevalence was 48.0% for CSs, 40.8% for aspirin and 6.0% for other NSAIDs and varied by pregnancy period. The prevalence of common medications among SLE pregnancies was 1.2- to 20-fold higher than among non-SLE pregnancies; for example, dalteparin (20.9 vs 1.0%), paracetamol (18.2 vs 2.9%) and levothyroxine (15.9 vs 4.9%). CONCLUSION: In nearly half of SLE pregnancies, women were dispensed DMARDs and CSs. Commonly used medications in SLE pregnancies had far higher prevalence estimates compared with non-SLE pregnancies. Research regarding benefits and risks of commonly used medications on SLE pregnancies, breast milk and long-term outcomes for offspring is needed.
引用
- Palmsten K, Simard JF, Chambers CD, et al. Medication use among pregnant women with systemic lupus erythematosus and general population comparators. Rheumatology (Oxford). 2017. PMID: 28013193. doi:10.1093/rheumatology/kew448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。